Latest News

Ignore the O'Hare lawsuit. Focus on valuation.

Which telecom giant is a stronger investment?

The GBP/USD forecast shows caution ahead of this week’s BoE policy meeting.

Nvidia has been the most popular chip stock for two years now, but another opportunity is emerging in the background.

Royal Caribbean and Norwegian Cruise Line were passing ships, but that's not a new itinerary for investors.

If bulls are winning back the market, these speedsters can help you stay ahead of your fellow investors.

The threat of 100% Trump tariffs on foreign-made movies sent Netflix stock, shares of movie studios and theater chains lower on Monday.

Fifth Third Bancorp operates through three segments: Commercial Banking, Consumer and Small Business Banking, and Wealth and Asset Management.

There's one great reason why Frontline is outperforming Exxon and Conoco stocks today.

Zimmer now expects 2025 adjusted profit per share in the range of $7.90 to $8.10, compared with its prior forecast of $8.15 to $8.35 per share.

Artificial intelligence infrastructure firm CoreWeave completed its purchase of Weights & Biases, which operates an AI developer platform.

Marvel Studios' Thunderbolts earned $76M domestically and $86.1M internationally in its opening weekend, compared to Eternals' and Ant-Man and the Wasp's openings.

Ripple (CRYPTO: XRP) has pledged $25 million to support U.S. K-12 classrooms and educators through partnerships with nonprofit organizations DonorsChoose and Teach For America.

Exxon Mobil shares fell 2.66% on Monday. Investors digested mixed Q1 earnings and fresh pressure on oil prices following an OPEC+ supply decision.

Faraday Future's (NASDAQ: FFAI) shares rise on new pre-order agreement for 300 units with non-refundable deposit. 1,000 units also pre-ordered last week.

Warren Buffett, CEO of Berkshire Hathaway, will step down in 2026. Tim Cook, Jim Cramer, and Bill Gates express admiration for Buffett. Stock down 5.87%.

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases.

Editor’s note: This article was originally published in July 2024. It was updated in May 2025 to reflect the continued growth of Educannabis.